Top Markets
Coin of the day
Proteonomix, Inc. Proteonomix, Inc.

Proteonomix, Inc.

PROT
Rang în acțiuni #42572
Proteonomix, Inc., a biotechnology company, focuses on developing therapeutics... Proteonomix, Inc., a biotechnology company, focuses on developing therapeutics based upon the use of human cells and their derivatives. The company’s products include Proteoderm, an anti-aging skin cream based on a proprietary and patented matrix of proteins that reduce wrinkles; UMK-121, a treatment for liver disease using a combination of two or three approved drugs to mobilize particular bone marrow stem cells; and StromaCel, a treatment for cardiac patients within two weeks of a myocardial infarction using stem cells derived from donor bone marrow and administered through IV solution to repair heart tissue. Its products also comprise NC-138, a proprietary matrix of proteins, which act on the skin to enhance activities that reduce wrinkles. The company was formerly known as National Stem Cell Holding, Inc. and changed its name to Proteonomix, Inc. in August 2008. Proteonomix, Inc. was incorporated in 1995 and is based in Hawthorne, New Jersey.
Preț acțiune
$0.0001
Ultima sincronizare: 2026-08-11
Capitalizare de piață
$791.00
Schimbare (1 zi)
0.00%
Schimbare (1 an)
9,900.00%
Țară
US
Tranzacționează Proteonomix, Inc. (PROT)

Categorie

Venituri pentru Proteonomix, Inc. (PROT)
Venituri în Aug 2026 TTM: 0
Conform celor mai recente rapoarte financiare ale Proteonomix, Inc., venitul actual al companiei (TTM) este 0. În anul 2026, compania a avut un venit de 0 egal cu venitul din anul 2026, care a fost de 0. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru Proteonomix, Inc. din 2026 până în 2026
Venituri la sfârșitul fiecărui an
An Venituri Schimbă
Nu sunt suficiente date pentru perioada selectată.
Venituri pentru companii similare sau concurente
Companie Venituri Diferență de venituri Țara
$12.62B -
US
$6.02B -
NL
- -
CH
$10.11B -
BE
- -
KR